Performance of 2-deoxy-2-[F-18]fluoro-D-glucose Positron Emission Tomography and Integrated PET/CT in Restaged Breast Cancer Patients

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2005 Oct 13

PMID 16220355

Citations 19

Authors

Barbara J Fueger

Wolfgang A Weber

Andrew Quon

Tyler L Crawford

M S Allen-Auerbach

B S Halpern

Osman Ratib

Michael E Phelps

Johannes Czernin

Affiliations

Soon will be listed here.

Abstract

Purpose: This study was conducted to compare the clinical stage derived from 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) positron emission tomography (PET) to that of integrated PET/computed tomography (CT) in restaged breast cancer patients.

Procedures: Fifty-eight female patients (age range 29-80 years, mean age +/-SD, 53.3 +/- 11.7 years) underwent PET/CT restaging for breast cancer. Two experienced nuclear medicine physicians interpreted PET images. A radiologist was added for reading PET/CT studies. A patient-based analysis was performed. Histopathological findings, correlative imaging studies, changes in number, size, and hypermetabolic activity of suspicious lesions and/or patient outcome served as standard of reference for determining the diagnostic accuracy of both modalities.

Results: PET staged 79.3% (46/58) of the patients correctly, overstaged seven (12.1%), and understaged five patients (8.6%). Integrated PET/CT staged 89.7% (52/58) of the patients correctly, overstaged four (6.9%), and understaged two patients (3.4%). The staging accuracy of PET/CT was not significantly better than that of PET alone (p = 0.059). Lesions exhibiting mild hypermetabolic activity, benign inflammatory lesions, and physiological variants largely explained incorrect PET findings.

Conclusion: Integrated PET/CT only marginally improves the restaging accuracy over PET alone (p = 0.059) in breast cancer patients.

Citing Articles

Angiogenesis versus Metabolic Imaging in Locally Advanced Breast Cancer Patients - A Comparative Study.

Kumar S, Vatsa R, Shukla J, Singh G, Bal A, Mittal B Indian J Nucl Med. 2022; 37(1):54-60.

PMID: 35478676 PMC: 9037866. DOI: 10.4103/ijnm.ijnm_53_21.

Higher Interrater Agreement of FDG-PET/CT than Bone Scintigraphy in Diagnosing Bone Recurrent Breast Cancer.

Holm J, Farahani Z, Gerke O, Baun C, Falch K, Hildebrandt M Diagnostics (Basel). 2020; 10(12).

PMID: 33260766 PMC: 7760596. DOI: 10.3390/diagnostics10121021.

Fluorodeoxyglucose positron emission tomography/computed tomography findings after percutaneous cryoablation of early breast cancer.

Adachi T, Machida Y, Fukuma E, Tateishi U Cancer Imaging. 2020; 20(1):49.

PMID: 32678029 PMC: 7364607. DOI: 10.1186/s40644-020-00325-y.

Screening for distant metastases in patients with ipsilateral breast tumor recurrence: the impact of different imaging modalities on distant recurrence-free interval.

Poodt I, Schipper R, de Greef B, Vugts G, Maaskant-Braat A, Jansen F Breast Cancer Res Treat. 2019; 175(2):419-428.

PMID: 30955183 PMC: 6533220. DOI: 10.1007/s10549-019-05205-z.

Whole-body F-fluorodeoxyglucose positron emission tomography-computed tomography (F-FDG PET/CT) for staging locally advanced breast cancer: A prospective study from a tertiary cancer centre in south India.

Gajjala S, Hulikal N, Kadiyala S, Kottu R, Kalawat T Indian J Med Res. 2018; 147(3):256-262.

PMID: 29923514 PMC: 6022380. DOI: 10.4103/ijmr.IJMR_1368_16.

References

Vesselle H, MIRALDI F . FDG PET of the retroperitoneum: normal anatomy, variants, pathologic conditions, and strategies to avoid diagnostic pitfalls. Radiographics. 1998; 18(4):805-23; discussion 823-4. DOI: 10.1148/radiographics.18.4.9672967. View

Wahl R, Cody R, Hutchins G, Mudgett E . Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991; 179(3):765-70. DOI: 10.1148/radiology.179.3.2027989. View

Zornoza G, Garcia-Velloso M, Sola J, Regueira F, Pina L, Beorlegui C . 18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol. 2004; 30(1):15-9. DOI: 10.1016/j.ejso.2003.10.010. View

McDonough M, DePeri E, Mincey B . The role of positron emission tomographic imaging in breast cancer. Curr Oncol Rep. 2003; 6(1):62-8. DOI: 10.1007/s11912-996-0011-y. View

Lardinois D, Weder W, Hany T, Kamel E, Korom S, Seifert B . Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003; 348(25):2500-7. DOI: 10.1056/NEJMoa022136. View

Rosenthal D . Radiologic diagnosis of bone metastases. Cancer. 1997; 80(8 Suppl):1595-607. DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1595::aid-cncr10>3.3.co;2-z. View

Avril N, Menzel M, Dose J, Schelling M, Weber W, Janicke F . Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med. 2001; 42(1):9-16. View

Redmond 3rd J, Spring D, Munderloh S, George C, Mansour R, Volk S . Spinal computed tomography scanning in the evaluation of metastatic disease. Cancer. 1984; 54(2):253-8. DOI: 10.1002/1097-0142(19840715)54:2<253::aid-cncr2820540212>3.0.co;2-f. View

Lind P, Igerc I, Beyer T, Reinprecht P, Hausegger K . Advantages and limitations of FDG PET in the follow-up of breast cancer. Eur J Nucl Med Mol Imaging. 2004; 31 Suppl 1:S125-34. DOI: 10.1007/s00259-004-1535-8. View

10.

BARRY Jr W, Wells Jr S, Cox C, Haagensen Jr D . Clinical and radiographic correlations in breast cancer patients with osseous metastases. Skeletal Radiol. 1981; 6(1):27-32. DOI: 10.1007/BF00347343. View

11.

Cook G, Fogelman I . Detection of bone metastases in cancer patients by 18F-fluoride and 18F-fluorodeoxyglucose positron emission tomography. Q J Nucl Med. 2001; 45(1):47-52. View

12.

Coleman R, Seaman J . The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases. Semin Oncol. 2001; 28(2 Suppl 6):11-6. DOI: 10.1016/s0093-7754(01)90260-x. View

13.

Yeung H, Grewal R, Gonen M, Schoder H, Larson S . Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET. J Nucl Med. 2003; 44(11):1789-96. View

14.

Avril N, Rose C, Schelling M, Dose J, Kuhn W, Bense S . Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000; 18(20):3495-502. DOI: 10.1200/JCO.2000.18.20.3495. View

15.

Hany T, Gharehpapagh E, Kamel E, Buck A, Himms-Hagen J, von Schulthess G . Brown adipose tissue: a factor to consider in symmetrical tracer uptake in the neck and upper chest region. Eur J Nucl Med Mol Imaging. 2002; 29(10):1393-8. DOI: 10.1007/s00259-002-0902-6. View

16.

Hernandez C, Majeska R, Schaffler M . Osteocyte density in woven bone. Bone. 2004; 35(5):1095-9. DOI: 10.1016/j.bone.2004.07.002. View

17.

van der Hoeven J, Hoekstra O, Comans E, Pijpers R, Boom R, van Geldere D . Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 2002; 236(5):619-24. PMC: 1422620. DOI: 10.1097/00000658-200211000-00012. View

18.

Hoh C, Schiepers C . 18-FDG imaging in breast cancer. Semin Nucl Med. 1999; 29(1):49-56. DOI: 10.1016/s0001-2998(99)80029-4. View

19.

Gallowitsch H, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P . F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging. Invest Radiol. 2003; 38(5):250-6. DOI: 10.1097/01.RLI.0000063983.86229.f2. View

20.

Yang S, Liang J, Lin F, Kao C, Lin C, Lee C . Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer. J Cancer Res Clin Oncol. 2002; 128(6):325-8. DOI: 10.1007/s00432-002-0342-5. View